{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:05:42Z","timestamp":1786993542532,"version":"build-2736575974"},"reference-count":27,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T00:00:00Z","timestamp":1677801600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003246","name":"Nederlandse Organisatie voor Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.jtha.2023.02.019","type":"journal-article","created":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T05:36:16Z","timestamp":1677821776000},"page":"1466-1477","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["A factor IX variant that functions independently of factor VIII mitigates the hemophilia A phenotype in patient plasma"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1530-0818","authenticated-orcid":false,"given":"Viola J.F.","family":"Strijbis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0348-658X","authenticated-orcid":false,"given":"Lorenzo G.R.","family":"Romano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ka Lei","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3268-5759","authenticated-orcid":false,"given":"Jeroen","family":"Eikenboom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9932-718X","authenticated-orcid":false,"given":"Ying Poi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew C.","family":"McCreary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5677-1371","authenticated-orcid":false,"given":"Frank W.G.","family":"Leebeek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8164-817X","authenticated-orcid":false,"given":"Mettine H.A.","family":"Bos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2023.02.019_bib1","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1182\/blood-2017-08-801662","article-title":"Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?","volume":"130","author":"Lenting","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.02.019_bib2","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1046\/j.1365-2516.2003.00780.x","article-title":"The epidemiology of inhibitors in haemophilia A: a systematic review","volume":"9","author":"Wight","year":"2003","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.02.019_bib3","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1182\/blood-2013-02-483263","article-title":"Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A","volume":"122","author":"Eckhardt","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.02.019_bib4","doi-asserted-by":"crossref","unstructured":"Srivastava A, Santagostino E, Dougall A, Kitchen S, Sutherland M, Pipe SW, Carcao M, Mahlangu J, Ragni MV, Windyga J, Llinas A, Goddard NJ, Mohan R, Poonnoose PM, Feldman BM, Lewis SZ, van den Berg HM, Pierce GF; WFH Guidelines for the Management of Hemophilia panelists and co-authors. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia 2020;26:1\u2013158.","DOI":"10.1111\/hae.14046"},{"key":"10.1016\/j.jtha.2023.02.019_bib5","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1056\/NEJMoa1104435","article-title":"Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors","volume":"365","author":"Leissinger","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2023.02.019_bib6","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1111\/j.1538-7836.2007.02663.x","article-title":"Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors","volume":"5","author":"Konkle","year":"2007","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.02.019_bib7","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/hae.12246","article-title":"Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors","volume":"20","author":"Antunes","year":"2014","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.02.019_bib8","first-page":"335","article-title":"Thrombotic events with recombinant activated factor VII (rFVIIa) in approved indications are rare and associated with older age, cardiovascular disease, and concomitant use of activated prothrombin complex concentrates (aPCC)","volume":"10","author":"Rajpurkar","year":"2019","journal-title":"J\u00a0Blood Med"},{"key":"10.1016\/j.jtha.2023.02.019_bib9","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jtha.2023.02.019_bib10","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/hae.14318","article-title":"Emicizumab prophylaxis: prospective longitudinal real-world follow-up and monitoring","volume":"27","author":"Barg","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.02.019_bib11","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1111\/jth.12731","article-title":"Next generation FIX muteins with FVIII-independent activity for alternative treatment of hemophilia A","volume":"12","author":"Quade-Lyssy","year":"2014","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.02.019_bib12","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1182\/blood-2011-05-353672","article-title":"Engineered factor IX variants bypass FVIII and correct hemophilia A phenotype in mice","volume":"119","author":"Milanov","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.02.019_bib13","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1182\/blood-2019-130875","article-title":"Novel thermostable inhibitor of contact activation tica effectively blocks contact activation in low tissue factor thrombin generation","volume":"134","author":"Van De Berg","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.02.019_bib14","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/s41467-017-00647-9","article-title":"Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors","volume":"8","author":"Verhoef","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtha.2023.02.019_bib15","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1159\/000071636","article-title":"Calibrated automated thrombin generation measurement in clotting plasma","volume":"33","author":"Hemker","year":"2003","journal-title":"Pathophysiol Haemost Thromb"},{"key":"10.1016\/j.jtha.2023.02.019_bib16","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12959-018-0164-6","article-title":"Thrombin generation in low plasma volumes","volume":"16","author":"Bloemen","year":"2018","journal-title":"Thromb J"},{"key":"10.1016\/j.jtha.2023.02.019_bib17","series-title":"Williams Hematology","article-title":"Molecular biology and biochemistry of the coagulation factors and pathways of hemostasis","author":"Bos","year":"2021"},{"key":"10.1016\/j.jtha.2023.02.019_bib18","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.thromres.2018.10.020","article-title":"Elevated coagulation factor levels affect the tissue factor-threshold in thrombin generation","volume":"172","author":"Rietveld","year":"2018","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2023.02.019_bib19","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s12185-020-02959-x","article-title":"A\u00a0modified thrombin generation assay to evaluate the plasma coagulation potential in the presence of emicizumab, the bispecific antibody to factors IXa\/X","volume":"112","author":"Ogiwara","year":"2020","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jtha.2023.02.019_bib20","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1111\/jth.13743","article-title":"Proposal for standardized preanalytical and analytical conditions for measuring thrombin generation in hemophilia: communication from the SSC of the ISTH","volume":"15","author":"Dargaud","year":"2017","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.02.019_bib21","doi-asserted-by":"crossref","first-page":"17241","DOI":"10.1074\/jbc.M312827200","article-title":"Formation of factors IXa and Xa by the extrinsic pathway: differential regulation by tissue factor pathway inhibitor and antithrombin III","volume":"279","author":"Lu","year":"2004","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jtha.2023.02.019_bib22","doi-asserted-by":"crossref","first-page":"5703","DOI":"10.1016\/S0021-9258(19)70686-3","article-title":"Kinetics of factor IX activation via the extrinsic pathway. Dependence of Km on tissue factor","volume":"255","author":"Zur","year":"1980","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jtha.2023.02.019_bib23","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1111\/jth.13134","article-title":"Thrombin generation assay using factor XIa to measure factors VIII and IX and their glycoPEGylated derivatives is robust and sensitive","volume":"13","author":"Waters","year":"2015","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.02.019_bib24","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1111\/j.1538-7836.2011.04358.x","article-title":"Thrombin generation assay using factor IXa as a trigger to quantify accurately factor VIII levels in haemophilia A","volume":"9","author":"Ninivaggi","year":"2011","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.02.019_bib25","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/hae.13597","article-title":"Evaluating the thrombin generation profiles of four different rFVIII products in FVIII-deficient plasma using FIXa and FXIa activation","volume":"24","author":"Brophy","year":"2018","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.02.019_bib26","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/jth.12474","article-title":"Anti-factor IXa\/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation","volume":"12","author":"Muto","year":"2014","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.02.019_bib27","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1111\/bjh.15126","article-title":"Factor XIa-triggered thrombin generation in severe haemophilia A","volume":"184","author":"Desborough","year":"2019","journal-title":"Br J Haematol"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153878362300168X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153878362300168X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:39:05Z","timestamp":1761536345000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S153878362300168X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S153878362300168X"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2023.02.019","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A factor IX variant that functions independently of factor VIII mitigates the hemophilia A phenotype in patient plasma","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2023.02.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}]}}